abstract |
Methods for treating inflammation and fibrosis symptoms in vivo using UG have been described. Also described are methods for the treatment or prevention of inflammation or fibrosis symptoms characterized by a deficiency in endogenous functional UG. Compositions containing UGs, optionally containing pulmonary surfactants, and assay procedures for detecting UG-fibronectin complexes are also provided. |